Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib

Krause G, Hassenrück F, Hallek M

Drug Design, Development and Therapy 2018, 12:2577-2590

Published Date: 21 August 2018